Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1NCT07517198
Official study title

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Study summary

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedEXS74539

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Small cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 10, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1

Interventional

Where is it offered?3 U.S. locations

Locations may change over time.

Who runs it?Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Interventions being studied
Drug: EXS74539
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→Small cell lung cancer (SCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Key
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Histologically confirmed diagnosis of the following solid tumors:
  • SCLC
  • High grade neuroendocrine or small cell carcinomas of non-lung origin
  • Non-small cell lung cancer \[NSCLC\]
  • Prostate cancer
  • Ovarian cancer
  • Renal carcinoma \[clear and non-clear cell\]
  • Head and neck squamous cell carcinoma
  • Hepatic cancer
  • Gastric cancer
  • Triple-negative breast cancer \[TNBC\]
  • Participant disease should have progressed, relapsed or the participants should have been intolerant to at least one prior standard systemic therapy for their respective underlying malignancy.
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Key
Reasons someone may not be able to joinExclusion criteria
  • Any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.
  • Symptomatic brain metastases, leptomeningeal metastases, or spinal cord compression due to disease. Participants with brain metastases must be clinically stable and off corticosteroids and anticonvulsants for ≥1 month prior to study treatment and not require any specific intervention for brain metastases.
  • Active and clinically significant infection requiring systemic antibacterial, antiviral, or antifungal therapy \<7 days of the first scheduled dose of the study treatment.
  • Significant cardiac abnormalities.
  • Major surgery within 28 days prior to the start of study treatment. Note: Other protocol-defined inclusion and

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Start LacnLos Angeles, California
  • START DallasFort Worth, Texas
  • START Mountain RegionWest Valley City, Utah

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 10, 2026. Always confirm current availability with the study team.

View original record ↗